NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report

The NOA‐03 trial explored high‐dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole‐brain radiotherap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of neurology 2005-06, Vol.57 (6), p.843-847
Hauptverfasser:	Herrlinger, Ulrich, Küker, Wilhelm, Uhl, Martin, Blaicher, Hans-Peter, Karnath, Hans-Otto, Kanz, Lothar, Bamberg, Michael, Weller, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimetabolites, Antineoplastic - administration & dosage Atrophy Bacterial diseases Biological and medical sciences Borrelia infections Brain Neoplasms - drug therapy Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - radiotherapy Combined Modality Therapy Human bacterial diseases Human viral diseases Humans Infectious diseases Lymphoma - drug therapy Lymphoma - mortality Lymphoma - pathology Lymphoma - radiotherapy Magnetic Resonance Imaging Medical sciences Methotrexate - administration & dosage Middle Aged Neurology Quality of Life Treatment Outcome Tropical bacterial diseases Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!